
## Zahra Mirzaasgari

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4333421/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Guillain–Barré syndrome as a parainfectious manifestation of SARS-CoV-2 infection: A case series. Journal of Clinical Neuroscience, 2021, 83, 119-122.	1.5	34
2	Toll-Like Receptor Signaling Pathways: Novel Therapeutic Targets for Cerebrovascular Disorders. International Journal of Molecular Sciences, 2021, 22, 6153.	4.1	25
3	Rituximab and risk of COVID-19 infection and its severity in patients with MS and NMOSD. BMC Neurology, 2021, 21, 183.	1.8	20
4	Post COVID-19 vaccination Guillain-Barre syndrome: three cases. Human Vaccines and Immunotherapeutics, 2022, 18, 1-5.	3.3	16
5	Longitudinally extensive transverse myelitis after Covid-19 vaccination: case report and review of literature. Human Vaccines and Immunotherapeutics, 2022, 18, 1-4.	3.3	15
6	Rivaroxaban for the treatment of cerebral venous thrombosis. BMC Neurology, 2021, 21, 73.	1.8	13
7	The predictive power of serum vitamin D for poor outcomes in COVIDâ€19 patients. Food Science and Nutrition, 2021, 9, 6307-6313.	3.4	6
8	Loss of vision after transurethral resection of prostate: A case report. Urology Case Reports, 2021, 38, 101739.	0.3	2
9	Investigation of time for hospital arrival in acute stroke patients in affiliated hospitals of Iran University of Medical Sciences in 2015. Journal of the Neurological Sciences, 2017, 381, 621.	0.6	1
10	Transbulbar B-mode sonography in multiple sclerosis without optic neuritis; clinical relevance. Brain Research, 2020, 1734, 146723.	2.2	1
11	An assessment on the use of infra-scanner for the diagnosis of the brain hematoma in head trauma. American Journal of Emergency Medicine, 2021, 55, 174-179.	1.6	1
12	National Guidelines for Cognitive Assessment and Rehabilitation of Iranian Traumatic Brain Injury Patients. Archives of Iranian Medicine, 2020, 23, 813-820.	0.6	1
13	Longitudinally extensive transverse myelitis after covid vaccination: Response to letter. Human Vaccines and Immunotherapeutics, 2022, 18, .	3.3	0